TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37781159

Group type: EXPERIMENTAL
Intervention: MAMMS (two-way SMS platform with MUAC tapes and weekly reminders)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: MAMMS (two-way SMS platform)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: SOC (standard care with routine community health volunteer services)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: SOC (standard care)
Number of subjects: 1200
Study: 37781160

Group type: EXPERIMENTAL
Intervention: Bandebereho programme (15-session intervention)
Number of subjects: 1199
Study: 37781161

Group type: EXPERIMENTAL
Intervention: AZD3759 at 200 mg bid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AZD3759 at 300 mg bid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AZD3759 (both doses combined)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients treated with osimertinib in a later-line setting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients treated without osimertinib in a later-line setting
Number of subjects: 30
Study: 37781463

Group type: EXPERIMENTAL
Intervention: Glucose-lowering agents (GLAs) with proven cardiovascular benefits
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Glucose-lowering agents (GLAs)
Number of subjects: 800
Study: 37781539

Group type: EXPERIMENTAL
Intervention: Plant-derived extracellular vesicles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammalian-derived extracellular vesicles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37781916

Group type: EXPERIMENTAL
Intervention: Caloric restriction (14% sustained CR for 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inducible SPARC downregulation in adult mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deletion of SPARC in adipocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPARC activation of NLRP3 inflammasome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downregulation of SPARC
Number of subjects: 0
Study: 37781954

Group type: COMPARATOR
Intervention: LZV (single dose subcutaneously)
Number of subjects: 90259

Group type: COMPARATOR
Intervention: RZV (two doses intramuscularly, two months apart)
Number of subjects: 90259

Group type: EXPERIMENTAL
Intervention: LZV (single dose) and RZV (two doses)
Number of subjects: 90259
Study: 37782145

Group type: EXPERIMENTAL
Intervention: MiniMed insulin pump therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 0
Study: 37782150

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 50% Maximal Inspiratory Pressure (MIP), 12 weeks, 3 days a week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group with IMT at 10% MIP
Number of subjects: 32
Study: 37782353

Group type: EXPERIMENTAL
Intervention: AG019 monotherapy (Phase 1b)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AG019 in combination with teplizumab (Phase 2a)
Number of subjects: 42
Study: 37782356

Group type: EXPERIMENTAL
Intervention: Serum uric acid (UA) levels in early pregnancy
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Serum UA above 240 μmol/l
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Pregnant women aged over 35 years and preBMI ≥ 24 kg/m
Number of subjects: 873

Group type: COMPARATOR
Intervention: Comparison with 78 healthy non-pregnant women
Number of subjects: 873
Study: 37782370

Group type: EXPERIMENTAL
Intervention: Global LUS score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LUS-ARDS score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anterior-lateral LUS score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: B-line score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ∆global LUS score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ∆anterior-lateral LUS score
Number of subjects: 30
Study: 37782421

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 2D T1-weighted gradient-echo sequences acquired at least 10 min after contrast injection (gadobutrol 0.1 mmol/kg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D T1-weighted gradient-echo sequences
Number of subjects: 1
Study: 37782540

Group type: EXPERIMENTAL
Intervention: Pinching Test features
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IMU-based features
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fatigability features
Number of subjects: 67
Study: 37782758

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 336
Study: 37782888

Group type: EXPERIMENTAL
Intervention: Intratumoral LSAM-PTX (15 mg/mL)
Number of subjects: 32
Study: 37782904

Group type: EXPERIMENTAL
Intervention: Control-IQ technology
Number of subjects: 0
Study: 37782930

Group type: EXPERIMENTAL
Intervention: Transient new-onset AF during hospitalization
Number of subjects: 139

Group type: COMPARATOR
Intervention: Matched control participants without AF
Number of subjects: 139
Study: 37783219

Group type: EXPERIMENTAL
Intervention: Injectable cabotegravir
Number of subjects: 570

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate plus emtricitabine
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 570
Study: 37783221

Group type: EXPERIMENTAL
Intervention: AZD1222
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: AZD2816
Number of subjects: 1394
Study: 37783378

Group type: EXPERIMENTAL
Intervention: Simnotrelvir alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 37783453

Group type: EXPERIMENTAL
Intervention: Cholera conjugate vaccine (CCV) OSP:rTTHc
Number of subjects: 0
Study: 37783456

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Peripheral blood sampling
Number of subjects: 148
Study: 37783459

Group type: EXPERIMENTAL
Intervention: Combined homestead food production and food hygiene intervention
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 574
Study: 37783480

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37783805

Group type: EXPERIMENTAL
Intervention: Ex vivo drug response profiling
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ex vivo resistance to chemotherapeutic drugs
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ex vivo response to chemotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ex vivo drug response profiles
Number of subjects: 80
Study: 37783947

Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37783966

Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin, plus nivolumab
Number of subjects: 76
Study: 37783969

Group type: EXPERIMENTAL
Intervention: Cloxacillin plus fosfomycin
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cloxacillin alone
Number of subjects: 215
Study: 37783970

Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy
Number of subjects: 88
Study: 37784006

Group type: EXPERIMENTAL
Intervention: lacosamide
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: eslicarbazepine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: perampanel
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: brivaracetam
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: topiramate
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: zonisamide
Number of subjects: 138
Study: 37784053

Group type: EXPERIMENTAL
Intervention: EGYFIL™ topical lotion
Number of subjects: 26
Study: 37784086

Group type: EXPERIMENTAL
Intervention: Group-based walking program (standard approach)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Group-based walking plus civic engagement program (combined approach)
Number of subjects: 400
Study: 37784098

Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription (DAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Immediate antibiotic prescription (IAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No antibiotic prescription (NAP)
Number of subjects: 39
Study: 37784109

Group type: EXPERIMENTAL
Intervention: Screening frequency (once vs. at least twice daily)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: SBT technique (pressure support + positive end-expiratory pressure)
Number of subjects: 760

Group type: COMPARATOR
Intervention: T-piece (as a comparison to pressure support + positive end-expiratory pressure)
Number of subjects: 760
Study: 37784110

Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline (5 g every 12 hours for 5 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (isonitrogenous, isocaloric)
Number of subjects: 120
Study: 37784131

Group type: EXPERIMENTAL
Intervention: Peak anti-Factor Xa values
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Trough anti-Factor Xa values
Number of subjects: 408
Study: 37784193

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score and physical activity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score
Number of subjects: 68
Study: 37784197

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise therapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training program with range of motion exercises
Number of subjects: 0
Study: 37784200

Group type: EXPERIMENTAL
Intervention: Walk-up no-cost testing
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Community health worker (promotores)-facilitated testing and preventive care counseling
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Vending machines dispensing no-cost, self-testing kits
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Implementation strategy bundle
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Community and Scientific Advisory Board (CSAB) engagement
Number of subjects: 7500
Study: 37784199

Group type: EXPERIMENTAL
Intervention: Active iTBS (intermittent theta burst stimulation) applied over the left dorsolateral prefrontal cortex (DLPFC) for ten sessions, once a day.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham iTBS applied over the left dorsolateral prefrontal cortex (DLPFC) for ten sessions, once a day.
Number of subjects: 96
Study: 37784232

Group type: EXPERIMENTAL
Intervention: Core stabilization training for 8 weeks, 5 days/week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 37786277

Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Active treatment in MAESTRO-NAFLD-OLE
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Resmetirom
Number of subjects: 2000
Study: 37786336

Group type: EXPERIMENTAL
Intervention: Resectoscope sheath size (specific size not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not mentioned)
Number of subjects: 0
Study: 37786390

Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose, 2500 mg)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 510
Study: 37786396

Group type: EXPERIMENTAL
Intervention: Tirzepatide (5 mg, 10 mg, 15 mg)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Insulin Lispro
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled)
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 1428
Study: 37786451

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tocilizumab 6 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tocilizumab (all doses)
Number of subjects: 12
Study: 37786680

Group type: EXPERIMENTAL
Intervention: Zotiraciclib (ZTR), a CDK9 inhibitor
Number of subjects: 0
Study: 37786777

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) for varying lengths (1 to 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study: 37786824

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 218
Study: 37787009

Group type: EXPERIMENTAL
Intervention: PEG-IFNa + TDF (180 μg PEG-IFNa weekly plus 300 mg TDF once daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PEG-IFNa + placebo (180 μg PEG-IFNa weekly plus placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PEG-IFNa + TDF
Number of subjects: 120

Group type: COMPARATOR
Intervention: PEG-IFNa + placebo
Number of subjects: 120
Study: 37787025

Group type: EXPERIMENTAL
Intervention: MAG-EPA (3.75 g daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: HOSO (3.75 g daily)
Number of subjects: 130
Study: 37787428

Group type: EXPERIMENTAL
Intervention: Transcutaneous sacral nerve stimulation (tSNS) with pelvic floor exercises (PFEs)
Number of subjects: 92
Study: 37787432

Group type: EXPERIMENTAL
Intervention: 10-Hz taVNS
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 25-Hz taVNS
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 300
Study: 37787643

Group type: EXPERIMENTAL
Intervention: Annual magnetic resonance with cholangiopancreatography or endoscopic ultrasound
Number of subjects: 156
Study: 37787644

Group type: EXPERIMENTAL
Intervention: Digital application tool for computing guideline-recommended follow-up intervals
Number of subjects: 29

Group type: COMPARATOR
Intervention: No access to the digital application (control group)
Number of subjects: 29
Study: 37787675

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) plus best medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical management alone
Number of subjects: 0
Study: 37787793

Group type: EXPERIMENTAL
Intervention: CPAP treatment (mean adherence 3.1 hours per day)
Number of subjects: 4186

Group type: EXPERIMENTAL
Intervention: Good adherence to CPAP (≥4 hours per day)
Number of subjects: 4186

Group type: COMPARATOR
Intervention: No CPAP (usual care)
Number of subjects: 4186
Study: 37787790

Group type: EXPERIMENTAL
Intervention: PD-1 blockade plus lenvatinib
Number of subjects: 103
Study: 37787796

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) with cuff pressure ≤200 mm Hg (n=749)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Sham treatment with cuff pressure 20 mm Hg (n=751)
Number of subjects: 1500
Study: 37787815

Group type: EXPERIMENTAL
Intervention: Integrative oncology (IO) treatment program
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: PCP narratives
Number of subjects: 597
Study: 37787888

Group type: EXPERIMENTAL
Intervention: Fixed-ratio combination (basal insulin + GLP-1RA)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Association of basal insulin plus an SGLT-2 inhibitor (gliflo-combo)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 305
Study: 37787906

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 123
Study: 37787941

Group type: EXPERIMENTAL
Intervention: 5-alpha-reductase inhibitors (5-ARIs)
Number of subjects: 7618

Group type: COMPARATOR
Intervention: No treatment (5-ARIs naïve)
Number of subjects: 7618
Study: 37788048

Group type: EXPERIMENTAL
Intervention: Self-Determination Theory (SDT)-driven intervention delivered via email, coupled with a wearable activity monitor and PA recommendations
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 37788049

Group type: EXPERIMENTAL
Intervention: PEER intervention (8-week Physio-Feedback Exercise Program)
Number of subjects: 340
Study: 37788060

Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training with neurofeedback assistance
Number of subjects: 92

Group type: COMPARATOR
Intervention: Mobile mindfulness training without neurofeedback
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-learning paper materials on stress management
Number of subjects: 92
Study: 37788078

Group type: EXPERIMENTAL
Intervention: Self-directed mobile and web-based intervention (Mission Reconnect) for veterans with chronic pain and PTSD
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Self-directed mobile and web-based intervention (Mission Reconnect)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 364
Study: 37788108

Group type: EXPERIMENTAL
Intervention: Agricultural livelihood intervention (water pump, seeds, agricultural and financial training)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Standard of HIV care (control)
Number of subjects: 720
Study: 37788412

Group type: EXPERIMENTAL
Intervention: 200 mg canakinumab once every 3 weeks for 18 cycles
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: 200 mg canakinumab
Number of subjects: 1382
Study: 37788414

Group type: EXPERIMENTAL
Intervention: Guideline-based PP-CSF standing order entry (SOE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alert to not prescribe PP-CSF
Number of subjects: 32
Study: 37788676

Group type: EXPERIMENTAL
Intervention: risankizumab 600 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: risankizumab 1200 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: risankizumab 180 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: risankizumab 360 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: placebo (withdrawal)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: risankizumab (induction)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: risankizumab (maintenance)
Number of subjects: 198
Study: 37788924

Group type: EXPERIMENTAL
Intervention: MAC treatment with macrolides, rifamycin, ethambutol, amikacin and/or fluoroquinolones
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drug exposure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minimum inhibitory concentration (MIC) determination
Number of subjects: 100
Study: 37788927

Group type: EXPERIMENTAL
Intervention: Intensified health education ('I')
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: RITe (transport reimbursement, intensified health education, and telephonic tracing)
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Full intervention (RITe)
Number of subjects: 2230

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Men with genital warts
Number of subjects: 2230
Study: 37788928

Group type: EXPERIMENTAL
Intervention: self-guided internet-delivered intervention
Number of subjects: 50
Study: 37789121

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 150
Study: 37789228

Group type: EXPERIMENTAL
Intervention: XJ-procedure group
Number of subjects: 183

Group type: COMPARATOR
Intervention: CARS group
Number of subjects: 183
Study: 37789266

Group type: EXPERIMENTAL
Intervention: Post-ICU patients (Bern cohort)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Post-ICU patients (Lausanne cohort)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Non-ICU patients
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Calprotectin levels
Number of subjects: 192
Study: 37789286

Group type: EXPERIMENTAL
Intervention: Quality Circle Deprescribing Module (QC-DeMo) intervention
Number of subjects: 26
Study: 37789300

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) solution
Number of subjects: 165

Group type: COMPARATOR
Intervention: 5% Sodium Fluoride (NaF) varnish combined with Motivational Interviewing (MI)
Number of subjects: 165
Study: 37789329

Group type: EXPERIMENTAL
Intervention: Ketofol 1:1 ratio
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ketofol 1:3 ratio
Number of subjects: 74
Study: 37789340

Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37789376

Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention using the MALPIP screening tool
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Number of subjects: 14
Study: 37789389

Group type: EXPERIMENTAL
Intervention: PBO-Pyrethroid LLIN
Number of subjects: 7471

Group type: COMPARATOR
Intervention: std-LLIN
Number of subjects: 7471
Study: 37789461

Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 528

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528
Study: 37790170

Group type: EXPERIMENTAL
Intervention: NIATx implementation strategies
Number of subjects: 53
Study: 37790171

Group type: EXPERIMENTAL
Intervention: TF-IDF method
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BERT method
Number of subjects: 113
Study: 37790186

Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TT) implementation support
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Enhanced train-the-trainer (TT+) implementation support
Number of subjects: 61
Study: 37790218

Group type: EXPERIMENTAL
Intervention: Attention training technique (ATT) delivered in groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 0
Study: 37790298

Group type: EXPERIMENTAL
Intervention: Neuromodulation (4 hours twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study: 37790304

Group type: EXPERIMENTAL
Intervention: Shorter nadir-to-regain (2-4 days)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Shorter nadir-to-regain (≤1 day)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Cumulative weight loss (-50 to <-23 percent-days)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Cumulative weight loss (≤-50 percent-days)
Number of subjects: 654
Study: 37790359

Group type: EXPERIMENTAL
Intervention: Telehealth delivery of nonpharmacologic care from physical therapists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Number of subjects: 0
Study: 37790374

Group type: EXPERIMENTAL
Intervention: Before school closures
Number of subjects: 0

Group type: COMPARATOR
Intervention: During school closures
Number of subjects: 0